GEN Exclusives

More »

GEN News Highlights

More »
Jun 20, 2008

Trubion Pharmaceuticals and Wyeth Lengthen Collaboration

  • Wyeth Pharmaceuticals has decided to extend its research collaboration with Trubion Pharmaceuticals for an additional year. For these additional research services, Trubion will receive approximately $3.2 million.

    The original agreement between the two companies was inked in December 2005 for the development and worldwide commercialization of TRU-015, Trubion’s lead product that is currently in Phase II development for the treatment of rheumatoid arthritis, and other CD20-directed therapeutics. The agreement also includes the development and worldwide commercialization of certain other product candidates directed to a small number of targets other than CD20.

    Related Links:

    Trubion Pharmaceuticals Announces Presentation of Positive TRU-015 and SBI-087 Data at the 2008 Annual European Congress of Rheumatology Meeting



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Block That Microbiome Metaphor!

Which way of thinking about the microbiome would best integrate the virome’s contributions?